Search research articles
Contact Us
Filters
Showing results (261-270 of 347) with videos related to
Page
of 35
Sort By:
Lung Cancer (Amsterdam, Netherlands)
|
November 29, 2020
Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6
Yi-Long Wu, Yuankai Shi, Daniel Shao Weng Tan, et al.
Cancer
|
December 22, 2023
Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray
Liyuan Dai, Haizhu Chen, Qiaoyun Tan, et al.
Molecular & Cellular Proteomics : MCP
|
July 27, 2023
Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
Ning Lou, Guibin Wang, Yanrong Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 31, 2024
Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study
Yuankai Shi, Xingsheng Hu, Xingya Li, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
January 30, 2023
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera<sup>®</sup>) in patients with CD20-positive B-cell non-Hodgkin lymphoma
Xiaohong Han, Mingzhi Zhang, Huaqing Wang, et al.
BMJ Open
|
June 3, 2019
Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China
Shiyu Jiang, Peng Liu, Sheng Yang, et al.
Eclinicalmedicine
|
September 17, 2024
Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer
Puyuan Xing, Shanbing Wang, Minghong Bi, et al.
Ejhaem
|
December 5, 2022
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
Jun Zhu, Xiaonan Hong, Yu Qin Song, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
February 27, 2015
Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis
Youwu Shi, Shengyu Zhou, Xiaohui He, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
November 7, 2015
Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
Bo Jia, Yuankai Shi, Suyi Kang, et al.
Page
of 35
Search research articles
Search
Showing results (261-270 of 347) with videos related to
Sort By:
Page
of 35
Lung Cancer (Amsterdam, Netherlands)
|
November 29, 2020
Phase 1/2 study of ceritinib in Chinese patients with advanced anaplastic lymphoma kinase-rearranged non-small cell lung cancer previously treated with crizotinib: Results from ASCEND-6
Yi-Long Wu, Yuankai Shi, Daniel Shao Weng Tan, et al.
Cancer
|
December 22, 2023
Identification of novel prognostic autoantibodies in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone via a high-throughput antigen microarray
Liyuan Dai, Haizhu Chen, Qiaoyun Tan, et al.
Molecular & Cellular Proteomics : MCP
|
July 27, 2023
Proteomics Identifies Circulating TIMP-1 as a Prognostic Biomarker for Diffuse Large B-Cell Lymphoma
Ning Lou, Guibin Wang, Yanrong Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
January 31, 2024
Ficonalkib (SY-3505) in Advanced ALK-Positive NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 1/2 Study
Yuankai Shi, Xingsheng Hu, Xingya Li, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
January 30, 2023
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera<sup>®</sup>) in patients with CD20-positive B-cell non-Hodgkin lymphoma
Xiaohong Han, Mingzhi Zhang, Huaqing Wang, et al.
BMJ Open
|
June 3, 2019
Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China
Shiyu Jiang, Peng Liu, Sheng Yang, et al.
Eclinicalmedicine
|
September 17, 2024
Phase 2 dose-ranging study to evaluate the efficacy and safety of liposomal irinotecan (LY01610) as a second-line treatment for patients with relapsed small cell lung cancer
Puyuan Xing, Shanbing Wang, Minghong Bi, et al.
Ejhaem
|
December 5, 2022
Ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone in patients with previously untreated non-germinal centre B-cell-like diffuse large B-cell lymphoma: A Chinese subgroup analysis of the phase III PHOENIX trial
Jun Zhu, Xiaonan Hong, Yu Qin Song, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
February 27, 2015
Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis
Youwu Shi, Shengyu Zhou, Xiaohui He, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu
|
November 7, 2015
Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma
Bo Jia, Yuankai Shi, Suyi Kang, et al.
Page
of 35